Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6269276 | 0.98 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6259741 | 0.98 | MEN1 (0.39) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13210383 | 0.95 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13210376 | 0.93 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13210377 | 0.93 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6255318 | 0.93 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL187033 | 0.88 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6256558 | 0.88 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6389445 | 0.88 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6259155 | 0.86 | MEN1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7709515-B2 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1204626-B1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS INC (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7192940-B2 | Ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6909014-B2 | Intermediates for the synthesis of ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | ESPERION THERAPEUTICS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-09-30 | — | — | US | disclosed |
| US-6790953-B2 | CARDIOVASCULAR DISORDERS, ANTIDIABETIC AGENTS, ALZHEIMER'S DISEASES, ANTIINFLAMMATOY AGENTS, ANTICANCER AGENTS | ESPERION THERAPEUTICS, INC. | 2004-09-14 | — | — | US | disclosed |
| US-20040082548-A1 | Intermediates for the synthesis of ether compounds | ESPERION THERAPEUTICS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6646170-B2 | Hydroxy derivatives; cardiovascular diseases, dyslipidemias, dysproteinemias, glucose metabolism disorders | ESPERION THERAPEUTICS, INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ESPERION THERAPEUTICS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030065195-A1 | Ether compounds | ESPERION THERAPEUTICS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-6506799-B1 | Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and | ESPERION THERAPEUTICS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6459003-B1 | ETHER COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS, METABOLISM DISORDERS AND CHOLESTEROL DISORDERS | ESPERION THERAPEUTICS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6410802-B1 | ETHERIFICATION IN PRESENCE OF BASE | ESPERION THERAPEUTICS, INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | MEN1 2288/4885KMT2A 3195/4885KDM4C 2980/4885 |
| US-20040082548-A1 | Intermediates for the synthesis of ether compounds | GPR119, PC, PPARG | MEN1 2436/4885KMT2A 2543/4885KDM4C 2084/4885 |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ECHS1, GPR119, PC | MEN1 2125/4885KMT2A 2871/4885KDM4C 2580/4885 |
| US-20030065195-A1 | Ether compounds | GPR119, PPARG, PNLIP | MEN1 2857/4885KMT2A 1925/4885KDM4C 1514/4885 |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | GPR119, NR1H2, PC | MEN1 3146/4885KMT2A 2112/4885KDM4C 2951/4885 |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | MEN1 2288/4885KMT2A 3195/4885KDM4C 2980/4885 |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | MEN1 2176/4885KMT2A 2080/4885KDM4C 2223/4885 |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | MEN1 2288/4885KMT2A 3195/4885KDM4C 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.